The New England Journal of Medicine Publishes Phase 3 Study of Epidiolex[®] (cannabidiol) in Dravet Syndrome

DRAVET SYNDROME^{1,2,3,4,5}

A rare, severe form of childhood-onset epilepsy that is difficult to treat

90%+ of children are resistant to treatment

90%+



There are no medications approved for Dravet syndrome in the U.S.

Affects between I in 20,000 to I in 40,000 children (over 5,400 people under the age of 20 in the U.S.)



~15%


Typically develops in the first year of life

Lifelong disease with frequent and prolonged seizures, intellectual disability, developmental delays and behavioral disturbances

> ~15% die within 10 years of diagnosis

STUDY DESIGN

(NCT02091375, sponsored by GW Research, Ltd. Full study design available at www.clinicaltrials.gov.)




PATIENTS IN THE STUDY

11



Had tried and failed a median of **4** other AEDs




2 STUDY ARMS (added to current treatment)



STUDY RESULTS

PRIMARY ENDPOINT



KEY SECONDARY ENDPOINTS

- More patients taking Epidiolex (43%) experienced a 50%+ reduction in convulsive seizures compared to placebo (27%)
- Significantly more caregivers reported that their child's overall condition improved with Epidiolex (62%) compared to placebo (34%)
- Total number of seizures was significantly reduced with Epidiolex compared to placebo

SAFETY

Epidiolex was generally well tolerated in this study. Adverse events (AEs) were consistent with previous data reported.



93% of Epidiolex patients and 75% of placebo patients experienced AEs
Most common AEs (>10%): somnolence, diarrhea, decreased appetite, fatigue, vomiting, pyrexia, lethargy, convulsion, upper respiratory tract infection

¹ http://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome² https://www.dravetfoundation.org/what-is-dravet-syndrome/³ Dravet C.The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl. 2):3–9.⁴ Cooper, M.S. et al. Mortality in Dravet syndrome. Epilepsy Research. 128 (2016) 43–47.⁵ Forsgren, L. Incidence and prevalence. in:Wallace SJ, Farrell K (Eds.) Epilepsy in children. 2nd edn. Arnold, London; 2004: 21–25.

These results establish the potential of Epidiolex as an important new medicine for those with Dravet syndrome. For full information and disclosures, see press release available at http://ir.gwpharm.com/releases.cfm

Epidiolex (cannabidiol) is an investigational product not approved for any condition in any country.